




The relative strengths and weaknesses of Rigel Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rigel Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Rigel Pharmaceuticals INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 306%, being 56% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	136,987
Cost of Goods Sold	287
Intangible Assets	0
Liabilities, Current	27,734
Liabilities, Non-Current	0
Other Assets	735
Other Compr. Net Income	2,261
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	44,509
Property and Equipment	1,387
Research and Development	46,903
Selling, General and Administrative Expense	70,002

Output Variable	Value in 1000 USD
Assets	139,109
Liabilities	27,734
Expenses	117,192
Revenues	44,509
Stockholders Equity	111,375
Net Income	-72,683
Comprehensive Net Income	-71,552
BaseVar	165,402
ECR before Limited Liability	205%
Economic Capital Ratio	306%